[Edaily Reporter Park Jung-Soo ] KOSDAQ-listed company Sonid(060230)achieved revenue growth and improved profitability in the first half of the year, driven by the inclusion of a subsidiary and business restructuring. JK Synapse announced on the 18th that its consolidated revenue for the first half of this year reached 47.299 billion won, a 136.9% increase compared to the same period last year (19.965 billion won). The revenue growth was driven by the inclusion of the newly acquired subsidiary, Selector, in the financial results. During the same period, the operating loss narrowed by 87.0% to 570 million won, compared to a loss of 4.398 billion won in the same period last year. Net income stood at 1.539 billion won, marking a return to profitability from the net loss of 10.032 billion won recorded in the same period last year. The company explained that this was driven by improvements in non-operating income and expenses, including business restructuring, the sale of non-core assets, and gains and losses related to derivatives. The financial structure also improved. Total consolidated equity at the end of this half-year stood at 72.221 billion won, a 21.2% increase from 59.612 billion won at the end of last year. This reflects capital expansion resulting from the payment of a rights offering and the conversion of convertible bonds (CBs). Consequently, the debt-to-equity ratio fell by 21.89 percentage points, from 145.24% at the end of last year to 123.35% at the end of this year’s first half. Cash and cash equivalents rose by 63.0% during the same period, from 2.939 billion won to 4.789 billion won. A JK Synapse official stated, “The first half of 2026 was a significant period in which we achieved both revenue growth and improved profitability,” adding, “In the second half, we will further solidify the foundation for sustainable growth by strengthening our core business competitiveness and implementing efficient financial management.”
(Photo: Blind)
One of the concerns facing the Lee Jae-myung administration is the decline in support among young people. According to Gallup Korea’s presidential job approval ratings, the approval…
The KRX Health Care Index rose 4.53% from the previous session on Oct. 1, signaling a rare tailwind for South Korea’s pharmaceutical and biotech sector. Among the gainers, GIInnovation and G2GBio drew…
(Graphic: ChatGPT)
“While existing ex vivo chimeric antigen receptor T-cell (CAR-T) therapies are personalized treatments that require cell collection from each patient for manufacturing, the in v…